Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Characterization and outcomes of severe complications after autologous hematopoietic stem-cell transplantation: a retrospective multicenter study.
Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the clinical characteristics and management and to identify factors associated with outcomes of patients requiring intensive care unit (ICU) admission after autologous hematopoietic stem-cell transplantation (ASCT).
designMulticenter retrospective observational cohort study.
settingEight university-hospital ICUs in France between January 2013 and July 2023. PATIENTS: Consecutive adults (≥ 18 years) admitted to the ICU within 90 days following ASCT conditioning.
interventionsNone. MEASUREMENTS AND MAIN
resultsAmong 6,342 ASCT recipients, 355 (5.6%) required ICU admission. Most had malignant lymphoma (60%) or multiple myeloma (34.6%). Admission typically occurred during the aplastic phase (median, 13 days after conditioning). Sepsis was the predominant diagnosis (75.9%), with the most common sources being neutropenic enterocolitis (more common in lymphoma) and pneumonia (more common in myeloma). Vasopressors were required in 181 (51%) patients and invasive mechanical ventilation in 121 (34.1%) patients. ICU mortality was 13.5% (48 patients) and 90-day mortality was 23.9% (85 patients). By multivariable analysis, factors independently associated with 90-day mortality were higher SAPS II score, lower serum albumin, performance status score ≥ 2, and lymphoma as the underlying malignancy. At one year, 209 (58.9%) patients were alive and in remission, including 198 (94.7%) with a good performance status.
conclusionsICU admission was required for 5.6% of patients after ASCT, chiefly during the neutropenic period. Although organ support was often required, good short- and long-term outcomes were obtained, with most survivors achieving a sustained remission and functional recovery. The clinical profiles differed between patients with myeloma and those with lymphoma, and the latter had lower survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.